Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 30 entries
Sorted by: Best Match Show Resources per page
Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel.

Neuropsychiatric disease and treatment

Bowirrat A, Cui J, Waraska K, Friedland RP, Oscar-Berman M, Farrer LA, Korczyn A, Baldwin CT.
PMID: 18568123
Neuropsychiatr Dis Treat. 2005 Mar;1(1):73-6. doi: 10.2147/nedt.1.1.73.52302.

The angiotensin-converting enzyme (ACE), a protease involved in blood pressure regulation, has been implicated as an important candidate gene for Alzheimer's disease (AD). This study investigated whether the ACE gene insertion-deletion (ID) polymorphism is associated with risk of developing...

Cite
Bowirrat A, Cui J, Waraska K, et al. Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel. Neuropsychiatr Dis Treat. 2005;1(1):73-6doi: 10.2147/nedt.1.1.73.52302.
Bowirrat, A., Cui, J., Waraska, K., Friedland, R. P., Oscar-Berman, M., Farrer, L. A., Korczyn, A., & Baldwin, C. T. (2005). Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel. Neuropsychiatric disease and treatment, 1(1), 73-6. https://doi.org/10.2147/nedt.1.1.73.52302
Bowirrat, Abdalla, et al. "Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel." Neuropsychiatric disease and treatment vol. 1,1 (2005): 73-6. doi: https://doi.org/10.2147/nedt.1.1.73.52302
Bowirrat A, Cui J, Waraska K, Friedland RP, Oscar-Berman M, Farrer LA, Korczyn A, Baldwin CT. Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel. Neuropsychiatr Dis Treat. 2005 Mar;1(1):73-6. doi: 10.2147/nedt.1.1.73.52302. PMID: 18568123; PMCID: PMC2426814.
Copy Download .nbib Format: NLM
Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine.

Journal of anesthesia

Gringauz M, Rabinowitz R, Stav A, Korczyn AD.
PMID: 14569437
J Anesth. 2001;15(4):204-9. doi: 10.1007/s005400170004.

PURPOSE: The increased use of opioids in the chronic treatment of pain, especially with oncologic patients, encourages the search for drugs with potent analgesic activity, but with minimal induced tolerance and cross-tolerance to morphine.METHODS: Four agonist-antagonist opioid derivatives (buprenorphine,...

Cite
Gringauz M, Rabinowitz R, Stav A, et al. Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. J Anesth. 2001;15(4):204-9doi: 10.1007/s005400170004.
Gringauz, M., Rabinowitz, R., Stav, A., & Korczyn, A. D. (2001). Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. Journal of anesthesia, 15(4), 204-9. https://doi.org/10.1007/s005400170004
Gringauz, M, et al. "Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine." Journal of anesthesia vol. 15,4 (2001): 204-9. doi: https://doi.org/10.1007/s005400170004
Gringauz M, Rabinowitz R, Stav A, Korczyn AD. Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. J Anesth. 2001;15(4):204-9. doi: 10.1007/s005400170004. PMID: 14569437.
Copy Download .nbib Format: NLM
Modeling the dementia epidemic.

CNS neuroscience & therapeutics

Treves TA, Korczyn AD.
PMID: 22070738
CNS Neurosci Ther. 2012 Feb;18(2):175-81. doi: 10.1111/j.1755-5949.2011.00242.x. Epub 2011 Mar 21.

The incidence of dementia increases steeply with age in older people, although from the tenth decade the slope may be smoother, perhaps reflecting different pathological processes in the oldest old. The prevalence depends upon interaction of age with other...

Cite
Treves TA, Korczyn AD. Modeling the dementia epidemic. CNS Neurosci Ther. 2011;18(2):175-81doi: 10.1111/j.1755-5949.2011.00242.x.
Treves, T. A., & Korczyn, A. D. (2012). Modeling the dementia epidemic. CNS neuroscience & therapeutics, 18(2), 175-81. https://doi.org/10.1111/j.1755-5949.2011.00242.x
Treves, T A, and Korczyn, A D. "Modeling the dementia epidemic." CNS neuroscience & therapeutics vol. 18,2 (2012): 175-81. doi: https://doi.org/10.1111/j.1755-5949.2011.00242.x
Treves TA, Korczyn AD. Modeling the dementia epidemic. CNS Neurosci Ther. 2012 Feb;18(2):175-81. doi: 10.1111/j.1755-5949.2011.00242.x. Epub 2011 Mar 21. PMID: 22070738; PMCID: PMC6493479.
Copy Download .nbib Format: NLM
Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice.

Journal of anesthesia

Kaadan M, Stav A, Rabinowitz R, Shavit S, Korczyn AD.
PMID: 23568116
J Anesth. 1994 Sep;8(3):297-300. doi: 10.1007/BF02514654.

An increase in the use of opioid derivatives in the treatment of pain syndrome in clinical practice, and especially in the treatment of cancer, has added impetus to the search for an agent which does not induce tolerance and...

Cite
Kaadan M, Stav A, Rabinowitz R, et al. Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice. J Anesth. 1994;8(3):297-300doi: 10.1007/BF02514654.
Kaadan, M., Stav, A., Rabinowitz, R., Shavit, S., & Korczyn, A. D. (1994). Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice. Journal of anesthesia, 8(3), 297-300. https://doi.org/10.1007/BF02514654
Kaadan, M, et al. "Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice." Journal of anesthesia vol. 8,3 (1994): 297-300. doi: https://doi.org/10.1007/BF02514654
Kaadan M, Stav A, Rabinowitz R, Shavit S, Korczyn AD. Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice. J Anesth. 1994 Sep;8(3):297-300. doi: 10.1007/BF02514654. PMID: 23568116.
Copy Download .nbib Format: NLM
Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes.

Parkinson's disease

Zlotnik Y, Balash Y, Korczyn AD, Giladi N, Gurevich T.
PMID: 25685594
Parkinsons Dis. 2015;2015:379482. doi: 10.1155/2015/379482. Epub 2015 Jan 15.

Awareness of nonmotor symptoms of Parkinson's disease is growing during the last decade. Among these, oral cavity disorders are, although prevalent, often neglected by the patients, their caregivers, and physicians. Some of these disorders include increased prevalence of caries...

Cite
Zlotnik Y, Balash Y, Korczyn AD, et al. Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes. Parkinsons Dis. 2015;2015:379482doi: 10.1155/2015/379482.
Zlotnik, Y., Balash, Y., Korczyn, A. D., Giladi, N., & Gurevich, T. (2015). Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes. Parkinson's disease, 2015379482. https://doi.org/10.1155/2015/379482
Zlotnik, Yair, et al. "Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes." Parkinson's disease vol. 2015 (2015): 379482. doi: https://doi.org/10.1155/2015/379482
Zlotnik Y, Balash Y, Korczyn AD, Giladi N, Gurevich T. Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes. Parkinsons Dis. 2015;2015:379482. doi: 10.1155/2015/379482. Epub 2015 Jan 15. PMID: 25685594; PMCID: PMC4312641.
Copy Download .nbib Format: NLM
Computerized diagnosis of mild cognitive impairment.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Aharonson V, Halperin I, Korczyn AD.
PMID: 19595913
Alzheimers Dement. 2007 Jan;3(1):23-7. doi: 10.1016/j.jalz.2006.10.001.

BACKGROUND: We previously described software that we have developed for use in the evaluation of mild cognitive impairment (MCI). Our previous study included an aged nondemented population with memory complaints (n = 41) that was relatively homogenous in terms...

Cite
Aharonson V, Halperin I, Korczyn AD. Computerized diagnosis of mild cognitive impairment. Alzheimers Dement. 2007;3(1):23-7doi: 10.1016/j.jalz.2006.10.001.
Aharonson, V., Halperin, I., & Korczyn, A. D. (2007). Computerized diagnosis of mild cognitive impairment. Alzheimer's & dementia : the journal of the Alzheimer's Association, 3(1), 23-7. https://doi.org/10.1016/j.jalz.2006.10.001
Aharonson, Vered, et al. "Computerized diagnosis of mild cognitive impairment." Alzheimer's & dementia : the journal of the Alzheimer's Association vol. 3,1 (2007): 23-7. doi: https://doi.org/10.1016/j.jalz.2006.10.001
Aharonson V, Halperin I, Korczyn AD. Computerized diagnosis of mild cognitive impairment. Alzheimers Dement. 2007 Jan;3(1):23-7. doi: 10.1016/j.jalz.2006.10.001. PMID: 19595913.
Copy Download .nbib Format: NLM
The tropicamide eye drop test in Parkinson's disease.

Parkinsonism & related disorders

Inzelberge R, Feiler V, Korzcyn AD.
PMID: 18591079
Parkinsonism Relat Disord. 1997 Dec;3(4):215-8. doi: 10.1016/s1353-8020(97)00023-0.

The dementia of Parkinson's disease (PD) and Alzheimer's disease (AD) share neurochemical and neuroanatomical characteristics. Pupillary supersensitivity to dilute pilocarpine and to the cholinergic antagonist tropicamide were described in AD, although the specificity has been debated. In the present...

Cite
Inzelberge R, Feiler V, Korzcyn AD. The tropicamide eye drop test in Parkinson's disease. Parkinsonism Relat Disord. 1997;3(4):215-8doi: 10.1016/s1353-8020(97)00023-0.
Inzelberge, R., Feiler, V., & Korzcyn, A. D. (1997). The tropicamide eye drop test in Parkinson's disease. Parkinsonism & related disorders, 3(4), 215-8. https://doi.org/10.1016/s1353-8020(97)00023-0
Inzelberge, R, et al. "The tropicamide eye drop test in Parkinson's disease." Parkinsonism & related disorders vol. 3,4 (1997): 215-8. doi: https://doi.org/10.1016/s1353-8020(97)00023-0
Inzelberge R, Feiler V, Korzcyn AD. The tropicamide eye drop test in Parkinson's disease. Parkinsonism Relat Disord. 1997 Dec;3(4):215-8. doi: 10.1016/s1353-8020(97)00023-0. PMID: 18591079.
Copy Download .nbib Format: NLM
Retraction: familial Alzheimer's disease associated with S182 codon 286 mutation.

Lancet (London, England)

Chapman J, Korczyn AD, Goldfarb LG.
PMID: 8691968
Lancet. 1996 Jul 20;348(9021):206. doi: 10.1016/s0140-6736(05)66162-4.

No abstract available.

Cite
Chapman J, Korczyn AD, Goldfarb LG. Retraction: familial Alzheimer's disease associated with S182 codon 286 mutation. Lancet. 1996;348(9021):206doi: 10.1016/s0140-6736(05)66162-4.
Chapman, J., Korczyn, A. D., & Goldfarb, L. G. (1996). Retraction: familial Alzheimer's disease associated with S182 codon 286 mutation. Lancet (London, England), 348(9021), 206. https://doi.org/10.1016/s0140-6736(05)66162-4
Chapman, J, et al. "Retraction: familial Alzheimer's disease associated with S182 codon 286 mutation." Lancet (London, England) vol. 348,9021 (1996): 206. doi: https://doi.org/10.1016/s0140-6736(05)66162-4
Chapman J, Korczyn AD, Goldfarb LG. Retraction: familial Alzheimer's disease associated with S182 codon 286 mutation. Lancet. 1996 Jul 20;348(9021):206. doi: 10.1016/s0140-6736(05)66162-4. PMID: 8691968.
Copy Download .nbib Format: NLM
CSF tau correlates with CJD disease severity and cognitive decline.

Acta neurologica Scandinavica

Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Nitsan Z, Appel S, Kahana E, Rosenmann H.
PMID: 26014384
Acta Neurol Scand. 2016 Feb;133(2):119-123. doi: 10.1111/ane.12441. Epub 2015 May 25.

BACKGROUND: Creutzfeldt-Jakob disease (CJD) is the most common prion disease in humans. The clinical diagnosis of CJD is supported by a combination of electroencephalogram, MRI, and the presence in the CSF of biomarkers. CSF tau is a marker for...

Cite
Cohen OS, Chapman J, Korczyn AD, et al. CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol Scand. 2015;133(2):119-123doi: 10.1111/ane.12441.
Cohen, O. S., Chapman, J., Korczyn, A. D., Warman-Alaluf, N., Nitsan, Z., Appel, S., Kahana, E., & Rosenmann, H. (2016). CSF tau correlates with CJD disease severity and cognitive decline. Acta neurologica Scandinavica, 133(2), 119-123. https://doi.org/10.1111/ane.12441
Cohen, O S, et al. "CSF tau correlates with CJD disease severity and cognitive decline." Acta neurologica Scandinavica vol. 133,2 (2016): 119-123. doi: https://doi.org/10.1111/ane.12441
Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Nitsan Z, Appel S, Kahana E, Rosenmann H. CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol Scand. 2016 Feb;133(2):119-123. doi: 10.1111/ane.12441. Epub 2015 May 25. PMID: 26014384.
Copy Download .nbib Format: NLM
Hamilton Depression Scale in dementia.

International journal of psychiatry in clinical practice

Kertzman SG, Treves IA, Treves TA, Vainder M, Korczyn AD.
PMID: 24931934
Int J Psychiatry Clin Pract. 2002;6(2):91-4. doi: 10.1080/136515002753724081.

INTRODUCTION: Wide variations in frequency of depression in primary degenerative dementia (PDD) and in vascular dementia (VD) have been reported. This may perhaps be due to inadequacy of common diagnostic tools in detecting depression in the face of cognitive...

Cite
Kertzman SG, Treves IA, Treves TA, et al. Hamilton Depression Scale in dementia. Int J Psychiatry Clin Pract. 2002;6(2):91-4doi: 10.1080/136515002753724081.
Kertzman, S. G., Treves, I. A., Treves, T. A., Vainder, M., & Korczyn, A. D. (2002). Hamilton Depression Scale in dementia. International journal of psychiatry in clinical practice, 6(2), 91-4. https://doi.org/10.1080/136515002753724081
Kertzman, Semion G, et al. "Hamilton Depression Scale in dementia." International journal of psychiatry in clinical practice vol. 6,2 (2002): 91-4. doi: https://doi.org/10.1080/136515002753724081
Kertzman SG, Treves IA, Treves TA, Vainder M, Korczyn AD. Hamilton Depression Scale in dementia. Int J Psychiatry Clin Pract. 2002;6(2):91-4. doi: 10.1080/136515002753724081. PMID: 24931934.
Copy Download .nbib Format: NLM
A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.

Dementia and geriatric cognitive disorders extra

Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U.
PMID: 24516413
Dement Geriatr Cogn Dis Extra. 2013 Dec 14;3(1):459-67. doi: 10.1159/000357122. eCollection 2013 Jan.

BACKGROUND: No drug treatment to date has shown convincing clinical evidence of restoring cognitive function or preventing further decline after stroke. The ongoing ARTEMIDA study will evaluate the efficacy and safety of Actovegin for the symptomatic treatment of post-stroke...

Cite
Guekht A, Skoog I, Korczyn AD, et al. A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dement Geriatr Cogn Dis Extra. 2013;3(1):459-67doi: 10.1159/000357122.
Guekht, A., Skoog, I., Korczyn, A. D., Zakharov, V., Eeg, M., & Vigonius, U. (2013). A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dementia and geriatric cognitive disorders extra, 3(1), 459-67. https://doi.org/10.1159/000357122
Guekht, Alla, et al. "A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design." Dementia and geriatric cognitive disorders extra vol. 3,1 (2013): 459-67. doi: https://doi.org/10.1159/000357122
Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U. A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dement Geriatr Cogn Dis Extra. 2013 Dec 14;3(1):459-67. doi: 10.1159/000357122. eCollection 2013 Jan. PMID: 24516413; PMCID: PMC3919431.
Copy Download .nbib Format: NLM
Drug treatment of Parkinson's disease.

Dialogues in clinical neuroscience

Korczyn AD.
PMID: 22033779
Dialogues Clin Neurosci. 2004 Sep;6(3):315-22.

Parkinson's disease (PD) is a common neurodegenerative disease. While its cause remains elusive, much progress has been made regarding its treatment. Available drugs have a good symptomatic effect, but none has yet been shown to slow the progression of...

Cite
Korczyn AD. Drug treatment of Parkinson's disease. Dialogues Clin Neurosci. 2004;6(3):315-22
Korczyn, A. D. (2004). Drug treatment of Parkinson's disease. Dialogues in clinical neuroscience, 6(3), 315-22.
Korczyn, Amos D. "Drug treatment of Parkinson's disease." Dialogues in clinical neuroscience vol. 6,3 (2004): 315-22.
Korczyn AD. Drug treatment of Parkinson's disease. Dialogues Clin Neurosci. 2004 Sep;6(3):315-22. PMID: 22033779; PMCID: PMC3181811.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 30 entries